Mollinedo Faustino, Gajate Consuelo
Centro de Investigaciones Biológicas Margarita Salas, Consejo Superior de Investigaciones Científicas (CSIC), Laboratory of Cell Death and Cancer Therapy, Department of Molecular Biomedicine, C/Ramiro de Maeztu 9, E-28040 Madrid, Spain.
Pharmaceutics. 2021 May 20;13(5):763. doi: 10.3390/pharmaceutics13050763.
The ether lipid edelfosine induces apoptosis selectively in tumor cells and is the prototypic molecule of a family of synthetic antitumor compounds collectively known as alkylphospholipid analogs. Cumulative evidence shows that edelfosine interacts with cholesterol-rich lipid rafts, endoplasmic reticulum (ER) and mitochondria. Edelfosine induces apoptosis in a number of hematological cancer cells by recruiting death receptors and downstream apoptotic signaling into lipid rafts, whereas it promotes apoptosis in solid tumor cells through an ER stress response. Edelfosine-induced apoptosis, mediated by lipid rafts and/or ER, requires the involvement of a mitochondrial-dependent step to eventually elicit cell death, leading to the loss of mitochondrial membrane potential, cytochrome release and the triggering of cell death. The overexpression of Bcl-2 or Bcl-xL blocks edelfosine-induced apoptosis. Edelfosine induces the redistribution of lipid rafts from the plasma membrane to the mitochondria. The pro-apoptotic action of edelfosine on cancer cells is associated with the recruitment of FF-ATP synthase into cholesterol-rich lipid rafts. Specific inhibition of the F sector of the FF-ATP synthase, which contains the membrane-embedded c-subunit ring that constitutes the mitochondrial permeability transcription pore, hinders edelfosine-induced cell death. Taking together, the evidence shown here suggests that the ether lipid edelfosine could modulate cell death in cancer cells by direct interaction with mitochondria, and the reorganization of raft-located mitochondrial proteins that critically modulate cell death or survival. Here, we summarize and discuss the involvement of mitochondria in the antitumor action of the ether lipid edelfosine, pointing out the mitochondrial targeting of this drug as a major therapeutic approach, which can be extrapolated to other alkylphospholipid analogs. We also discuss the involvement of cholesterol transport and cholesterol-rich lipid rafts in the interactions between the organelles as well as in the role of mitochondria in the regulation of apoptosis in cancer cells and cancer therapy.
醚脂类药物依地福新可选择性诱导肿瘤细胞凋亡,是一类合成抗肿瘤化合物家族的原型分子,这类化合物统称为烷基磷脂类似物。越来越多的证据表明,依地福新可与富含胆固醇的脂筏、内质网(ER)和线粒体相互作用。依地福新通过将死亡受体和下游凋亡信号募集到脂筏中,诱导多种血液系统癌细胞凋亡,而在实体瘤细胞中,它通过内质网应激反应促进凋亡。由脂筏和/或内质网介导的依地福新诱导的凋亡,需要线粒体依赖性步骤的参与才能最终引发细胞死亡,导致线粒体膜电位丧失、细胞色素释放并触发细胞死亡。Bcl-2或Bcl-xL的过表达可阻断依地福新诱导的凋亡。依地福新可诱导脂筏从质膜重新分布到线粒体。依地福新对癌细胞的促凋亡作用与F0F1-ATP合酶募集到富含胆固醇的脂筏中有关。对F0F1-ATP合酶F扇区的特异性抑制,该扇区包含构成线粒体通透性转换孔的膜嵌入c亚基环,会阻碍依地福新诱导的细胞死亡。综上所述,此处所示证据表明,醚脂类药物依地福新可通过与线粒体直接相互作用,以及对关键调节细胞死亡或存活的脂筏定位线粒体蛋白进行重组,来调节癌细胞的细胞死亡。在此,我们总结并讨论线粒体在醚脂类药物依地福新抗肿瘤作用中的参与情况,指出该药物的线粒体靶向作用是一种主要的治疗方法,这一方法可推广到其他烷基磷脂类似物。我们还讨论了胆固醇转运和富含胆固醇的脂筏在细胞器间相互作用中的作用,以及线粒体在癌细胞凋亡调控和癌症治疗中的作用。